Video: Dual-Action Gene Therapy for DME Shows Safety and Durability

David Almeida, MD, presented interim data from the SPECTRA trial of 4D-150 gene therapy in adults with diabetic macular edema

By: DAVID R.P. ALMEIDA, MD, MBA, PHD

Retinal Physician August 1, 2025 Vol 22, Issue July/August 2025

David R.P. Almeida

Investigator

Affiliations: Erie Retina Research and the Centers for Advanced Surgical Exploration (caseX)

Specialties: Retina

Bio: David R.P. Almeida, MD, MBA, PhD, is an investigator with Erie Retina Research and the Centers for Advanced Surgical Exploration (caseX). His work includes clinical research in retina, including diabetic macular edema and investigational intravitreal gene therapy. At the 2025 American Society of Retina Specialists annual meeting, Dr. Almeida presented interim results from SPECTRA, a phase 2a multicenter trial evaluating 4D-150 for adults with diabetic macular edema. The study assessed safety and clinical activity after aflibercept loading injections followed by a single 4D-150 injection.

PentaVision

Retinal Physician

Video: Dual-Action Gene Therapy for DME Shows Safety and Durability

Recommendations